SCHEMBL5360936

SCHEMBL5360936

O=C1Nc2ccc(S(=O)(=O)Nc3ccc(C(F)(F)F)cc3)cc2C1=Cc1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 4/20 0.54
GSK3B P49841 2/20 0.52
MGAT2 Q10469 3/20 0.51
TLK2 Q86UE8 3/20 0.47
PRKDC P78527 1/20 0.44
PKM P14618 1/20 0.43
PKLR P30613 1/20 0.43
AR P10275 1/20 0.42
IDH2 P48735 1/20 0.42
OXTR P30559 1/20 0.41
AVPR1A P37288 1/20 0.41
BRD4 O60885 1/20 0.41
MEN1 O00255 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357745 0.85 MOGAT2 (0.58) MOGAT2GSK3BMGAT2PRKDCPKM
SCHEMBL5357697 0.85 MOGAT2 (0.56) MOGAT2MGAT2TLK2PRKDCPKM
SCHEMBL7132931 0.85 MOGAT2 (0.52) MOGAT2MGAT2TLK2PRKDCPKM
SCHEMBL5362279 0.85 MOGAT2 (0.57) MOGAT2MGAT2TLK2PRKDCMEN1
SCHEMBL5358368 0.84 MOGAT2 (0.61) MOGAT2GSK3BMGAT2TLK2MEN1
SCHEMBL7131379 0.84 MOGAT2 (0.57) MOGAT2MGAT2PRKDCBRD4MEN1
SCHEMBL5365019 0.83 TLK2 (0.67) MOGAT2MGAT2TLK2
SCHEMBL7133809 0.83 MOGAT2 (0.50) MOGAT2MGAT2TLK2PRKDCPKM
SCHEMBL7137726 0.83 MOGAT2 (0.57) MOGAT2MGAT2TLK2PRKDCPKM
SCHEMBL5366350 0.83 GSK3B (0.53) MOGAT2GSK3BMGAT2TLK2PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885GSK3B 315/4885MGAT2 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.